-
REV1–DHX36 Control of G-Quadruplex Replication
2026-09-10
A 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. The work provides a mechanistic framework for interpreting G4-induced replication stress and for designing experiments that connect replication tolerance with DNA damage response signaling.
-
Escitalopram: Mechanism and Research Benchmarks
2026-09-10
Escitalopram, also known as Lexapro, is an S-enantiomer-selective serotonin transporter inhibitor with strong in vitro selectivity for serotonin uptake. Its molecular pharmacology supports antidepressant research and serotonergic signaling studies, while clinical augmentation evidence shows that apparent anxiolytic effects require careful interpretation.
-
Lassa Virus Spike pH Changes and Inhibition
2026-09-09
The reference study defines how acidity reshapes the Lassa virus spike before membrane fusion, linking early transmembrane-domain remodeling to later receptor release and spike opening. High-resolution structural analysis and ARN-75039 validation provide a mechanistic framework for understanding LASV entry and for evaluating entry-directed antiviral strategies.
-
MG-262 and the Proteostasis Logic of Muscle Aging
2026-09-09
A translational framework for using MG-262 (Z-Leu-Leu-Leu-B(OH)2) to connect proteasome activity, chaperone-mediated autophagy, calcium homeostasis, and muscle aging research.
-
Gut-Brain Cholinergic Signaling in Seizure Control
2026-09-08
Jia et al. identify a gut-brain mechanism through which Bacteroides fragilis suppresses seizures: activation of colonic ChAT-positive cells enhances cholinergic signaling through the vagus nerve, with associated Lactobacillus enrichment. The combination of mouse experiments and a randomized clinical trial provides a mechanistic framework for microbiota-targeted treatment research in pediatric refractory epilepsy.
-
Telatinib (BAY 57-9352) Research Workflows
2026-09-08
Build mechanism-aware angiogenesis, invasion, and combination-treatment assays with Telatinib rather than relying on viability alone. This workflow translates HER2–VEGFR2 findings in triple-negative breast cancer into practical dosing, endpoint selection, and troubleshooting decisions.
-
CCG-1423 RhoA Inhibitor Workflows
2026-09-07
CCG-1423 provides a mechanistically distinct way to interrogate RhoA transcriptional signaling through MRTF-A nuclear import, rather than treating cytoskeletal remodeling as a single endpoint. This workflow connects cancer research assays with a carefully qualified MVC tight-junction model, emphasizing orthogonal readouts, fresh dosing, and clear limits on interpretation.
-
Nonivamide for TRPV1 and Cancer Research
2026-09-05
Nonivamide combines selective TRPV1 stimulation with measurable anti-proliferative activity, making it useful for both neuroimmune assays and cancer cell studies. This guide translates the latest somatosensory-reflex findings into practical workflows while addressing solvent control, assay timing, and interpretation limits.
-
Humanized Mice Clarify CES Prodrug Metabolism
2026-09-05
The 2025 reference study shows that humanized-liver mice can substantially improve prediction of carboxylesterase-mediated prodrug conversion, using HD56 and its active metabolite HD561 as a model system. Its integrated transport, enzyme-phenotyping, microsomal, plasma, and pharmacokinetic design provides a practical framework for interpreting species differences and building more reliable in vivo–in vitro correlations.
-
Clasto-Lactacystin β-lactone and Viral Immune Evasion
2026-09-04
Proteasome inhibition is more than a stress-inducing endpoint: it is a mechanistic tool for testing how targeted protein degradation reshapes necroptosis, antiviral inflammation, and translational assay design. This article uses the vIRD–RIPK3 axis as a framework for applying Clasto-Lactacystin β-lactone with greater experimental precision.
-
Puromycin dihydrochloride: Cell Selection Guide
2026-09-04
Puromycin dihydrochloride provides a practical way to select and maintain cells expressing the pac resistance gene while also serving as a controlled protein synthesis inhibitor. It should be optimized by cell type and exposure schedule, and it is not appropriate for puromycin-sensitive systems when nonspecific translation inhibition would confound interpretation.
-
Aneugen Mechanism Assay: Evidence From 27 Chemicals
2026-09-03
Bernacki and colleagues developed a tiered flow-cytometric strategy to distinguish tubulin stabilization, tubulin destabilization, and mitotic kinase inhibition as causes of chemical-induced aneugenicity. Across 27 reference chemicals, the workflow combined DNA-damage and cell-cycle biomarkers with Taxol-associated fluorescence, p-H3, Ki-67, clustering, and machine learning to achieve strong mechanism classification.
-
Zolmitriptan 5-HT1B Receptor Agonist Workflows
2026-09-03
Build reproducible migraine and cluster headache assays with Zolmitriptan, a selective serotonin-receptor tool suited to receptor-proximal, vascular, and neuropeptide-release workflows. This guide combines practical stock preparation, time-resolved assay design, subtype controls, and troubleshooting with a cautious methods bridge to recent lysosomal research.
-
Prednisone Workflows for Immunology Research
2026-09-02
Prednisone provides a mechanistically anchored way to model G1 arrest, IL-2 pathway suppression, and lymphocyte apoptosis in controlled cell-based experiments. This guide combines practical handling, time-resolved PBL workflows, neurodegeneration applications, and LC–MS-informed quality controls for more reproducible results.
-
EPZ5676: Selective DOT1L Inhibitor for Leukemia
2026-09-02
EPZ5676 is a potent and selective DOT1L inhibitor that targets the SAM-binding pocket and suppresses H3K79 methylation. Its reported biochemical potency, MV4-11 antiproliferative activity, and xenograft regression data support use as a research tool for MLL-rearranged leukemia treatment studies, not as evidence of clinical efficacy.